Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P25791

UPID:
RBTN2_HUMAN

ALTERNATIVE NAMES:
Cysteine-rich protein TTG-2; LIM domain only protein 2; T-cell translocation protein 2

ALTERNATIVE UPACC:
P25791; Q9HD58

BACKGROUND:
Rhombotin-2, identified by its alternative names such as Cysteine-rich protein TTG-2 and LIM domain only protein 2, is integral to the regulation of erythroid precursor development. By collaborating with TAL1/SCL and LDB1, it maintains these precursors in an undifferentiated state, which is crucial for proper red blood cell formation.

THERAPEUTIC SIGNIFICANCE:
The exploration of Rhombotin-2's function presents a promising frontier for drug discovery. Given its essential role in the maintenance and development of erythroid precursors, targeting Rhombotin-2 could lead to innovative treatments for diseases related to red blood cell development and maintenance.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.